Successful systemic fibrinolysis in a patient with Covid- 19: Case report
The new coronavirus 2019-nCov or SARS-Cov-2 is responsible for the most important pandemic in the 21st century: the coronavirus disease (COVID-19).
The 2019-nCov infection elicits a hyper-coagulable state, conditioning a worse outcome in these patients. The pathophysiology of the exaggerated coagulation activation in these patients is still unknown, and probably involves several mechanisms, different from those involved in sepsis-associated coagulopathy.
This article discusses the case of a patient with no remarkable medical history, who after 7 days of fever, diarrhea and epigastric pain was diagnosed with COVID-19 bilateral pneumonia, further aggravated by severe Acute Respiratory Distress Syndrome. In this context, the patient experienced a massive acute pulmonary thromboembolism accompanied by an acute thrombus in the heart’s right ventricle, leading to hemodynamic instability. For the first time in our center in these patients, systemic fibrinolysis was successfully performed, with resolution of the intracavitary thrombus and the acute hemodynamic shock.
Domínguez-Gil B, Coll E, Fernández‐Ruiz M, Corral E, del Río F, Zaragoza R, et al. COVID‐19 In Spain: Transplantation In The Midst Of The Pandemic. Am J Transplant. 2020;20:2593–8. doi: http://dx.doi.org/10.1111/ajt.15983.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi: http://dx.doi.org/10.1016/S0140-6736(20)30183-5
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associa-ted with poor prognosis in patients with novel coronavirus pneumonia. J ThrombHaemost. 2020;18(4):844-847. doi: https://dx.doi.org/10.1111/jth.14768
Chong PY, Chui P, Ling AE, et al. Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis [J]. Arch Pathol Lab Med. 2004;128(2):195-204.
Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic com-plications in critically ill ICU patients with COVID-19. Thromb Res. 2020;S0049-3848(20)30120-1. doi: https://dx.doi.org/10.1016/j.thromres.2020.04.013
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lan-cet. 2020;395:1054-1062. doi: https://doi.org/10.1016/S0140-6736(20)30566-3
Zakai NA, McClure LA. Racial differences in venous thromboembolism. J ThrombHaemost. 2011;9(10):1877-1882. doi: http://dx.doi.org/10.1111/j.1538-7836.2011.04443.x
Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is as-sociated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J ThrombHaemost. 2020;18:1094–1099. doi: https://doi.org/10.1111/jth.14817
Paranjpe I, Fuster V, Lala A, Russak A, Glicksberg BS, Levin MA, et al. As-sociation of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19. Journal of the American College of Car-diology. 2020;76(1):122-4. doi: https://doi.org/10.1016/j.jacc.2020.05.001.
Kollias A, Kyriakoulis KG, Dimakakos E, Poulakou G, Stergiou GS, Syrigos K. Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emer-ging evidence and call for action. Br J Haematol. 2020. doi: https://doi.org/10.1111/bjh.16727
Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disea-se 2019 in China. N Engl J Med. 2020;382:1708-20. doi: https://doi.org/10.1056/NEJMoa2002032
Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J ThrombHaemost. 2020;18:1023-1026. Disponible en: https://doi.org/10.1111/jth.14810
Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020;46:1089-98. doi: https://doi.org/10.1007/s00134-020-06062-x